Good Doctor·Hyperthermic Perfusion | Bringing the “Effective Treatment Temperature” Truly into Hyperthermia Clinical Practice

From the ancient doctrine in the writings of Hippocrates of ancient Greece—that “iron (surgery) and fire (heat) can cure diseases”—to modern medicine’s precise breakthroughs in hyperthermia technology, hyperthermia has always shone with the light of wisdom throughout humanity’s journey in fighting tumors. Following this millennia-old path of medical exploration, Xi’an Good Doctor Medical Science and Technology Co., Ltd. has grounded itself in clinical needs and delved deeply into the field of intracavitary hyperthermic perfusion therapy. With professional dedication, the company stays true to its original aspiration; with meticulous craftsmanship, it refines core technologies. Relying on more than two decades of R&D and clinical experience, the company is boldly ushering in a new chapter in intracavitary hyperthermic perfusion therapy, using precise and standardized medical techniques to solve challenging clinical diagnostic and treatment problems. In doing so, it ensures that “effective intracavitary hyperthermic chemotherapy” truly enters clinical practice, safeguards the hope for life of every cancer patient with professional strength, and demonstrates the mission and responsibility of a national medical enterprise.

01 History of Intraperitoneal Hyperthermic Perfusion Chemotherapy (HIPEC)

Network Diagram: The “Father of Medicine,” Hippocrates, Left Behind the Precious Record That “High Fever Can Cure Tumors”

As early as ancient Greece, the “Father of Medicine,” Hippocrates, keenly recognized the link between high fever and cancer treatment, leaving behind the invaluable observation that “high fever can cure tumors.” Fast forward to the late 19th century, when a German physician serendipitously discovered that in some cancer patients who developed febrile infections, their tumors would spontaneously regress. This groundbreaking finding provided the initial impetus for clinical exploration of thermotherapy, bringing the concept of “using heat to fight cancer” from mere speculation to the threshold of practical application.

Network Diagram: The Emergence of Thermotherapy in the 19th Century
During the 1960s and 1970s, groundbreaking advances in medical research led scientists to formally demonstrate that a sustained body-temperature environment of 42°C to 43°C can selectively kill cancer cells while sparing normal tissues. More importantly, when combined with chemotherapeutic agents, this temperature range produces a synergistic sensitization effect, markedly enhancing the efficacy of chemotherapy. This discovery laid a solid scientific foundation for intracavitary hyperthermic perfusion therapy and provided clear medical evidence for the concept of “effective hyperthermia.”

Figure: Intraoperative Hyperthermic Peritoneal Perfusion for Peritoneal Cancer

At the First International Conference on Hyperthermia in Oncology, held in Washington, D.C., in 1975, hyperthermia was officially recognized as the fifth modality of treatment for malignant tumors.

The formal emergence of modern hyperthermic intraperitoneal chemotherapy (HIPEC) dates back to a pivotal breakthrough in 1979–1980. In 1979, the team led by Spratt at the University of Louisville in Kentucky successfully performed the world’s first cytoreductive surgery (CRS) combined with HIPEC for pseudomyxoma peritonei, thereby breaking the clinical bottleneck that had long constrained the application of intracavitary hyperthermic chemotherapy. The following year, the same group formally published a case report (Spratt JS et al., Cancer Research, 1980;40:256–260), introducing the therapeutic paradigm of “cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS+HIPEC),” which marked the official birth of modern intracavitary hyperthermic therapy. Subsequently, Professor Sugarbaker further advanced the clinical adoption of this technique, establishing it as a major milestone in the treatment of peritoneal metastatic cancer and offering a new therapeutic option to countless patients with malignancies.

02 Clinical Pain Points of “Effective Intracavitary Hyperthermic Perfusion Chemotherapy”

Despite millennia of exploration and successive breakthroughs that have gradually established a comprehensive theoretical and technical framework for hyperthermia, this medical ideal still encounters numerous insurmountable barriers when it is translated into clinical practice to benefit patients.

In the early days, hyperthermic intraperitoneal perfusion (HIPEC) involved merely heating the infusion solution in the bottle and instilling it directly into the body cavity; the temperature fluctuated unpredictably and it was difficult to maintain an effective therapeutic level. Moreover, because the perfusate remained static, heat distribution was suboptimal and uneven. In contrast, extracorporeal radiofrequency abdominal irradiation for heating requires the thermal energy to pass through the skin, subcutaneous tissue, fat, and muscle before reaching the body cavity; achieving an effective therapeutic temperature inevitably causes substantial damage to these intervening tissues. Furthermore, the non-uniform heat distribution not only leads to inconsistent therapeutic outcomes but also increases the risk of injury to normal tissues, thereby imposing additional pain on patients.

With the advancement of technology, subsequent methods such as water bath, microwave, and electromagnetic heating have emerged. However, most hyperthermic intraperitoneal perfusion (HIPP) devices currently available on the market still suffer from long heating cycles—typically requiring 10 to 15 minutes to reach the therapeutic temperature—and have yet to overcome the core technical bottleneck: achieving uniform, constant-temperature perfusion across the entire abdominal cavity, real-time precise temperature control, and safe, stable circulation. Moreover, the early HIPP techniques were characterized by complex procedures, significant invasiveness, and relatively high risks, which deterred many patients—particularly the elderly and those in frail health—from pursuing this therapy and thereby limited the clinical benefits that could be derived from hyperthermia treatment.

03 Bringing “Effective Intracavitary Hyperthermic Perfusion Chemotherapy” Fully into Clinical Practice

To truly bring “effective intracavitary hyperthermic perfusion chemotherapy” into clinical practice, Xi’an Good Doctor has been dedicated to R&D and clinical technological innovation for more than two decades, upholding a strong sense of responsibility and mission, and providing scientific, innovative, and practical specialized solutions for “preventing and treating tumor cavity implantation metastasis, eliminating minimal residual tumor foci, and treating malignant effusions.”

Led personally by Dr. Li, the pioneer of minimally invasive intracavitary hyperthermic perfusion therapy and a member of the professional team, a well-rounded talent pool has been assembled in Xi’an, comprising senior, mid-career, and young professionals from Good Doctor. The team brings together medical professors with 25 to 30 years of clinical experience, experts in the field of medical engineering, as well as professor-level and senior engineers specializing in mechanical design and manufacturing. Through the collaborative efforts of these diverse professionals, robust support is provided for both technological R&D and clinical application. Animal experiments: “A Study on the Safety of Intracavitary Circulatory Hyperthermic Perfusion Chemotherapy.”

Figure: Animal Study on the Optimal and Safe Temperature for HIPEC Treatment

Objective: To investigate the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) performed at different temperatures on the vital signs and intra-abdominal organs of experimental animals (dogs), with the aim of determining the optimal and safest temperature for HIPEC treatment.

Results: Intraperitoneal hyperthermic perfusion with 41°C saline plus cisplatin for 1 hour, administered three times, had no significant impact on the dogs’ vital signs or hepatic and renal function, with only mild injury to the liver, kidneys, spleen, and intestinal tissues. Similarly, intraperitoneal hyperthermic perfusion with 42°C saline plus cisplatin for 1 hour, also administered three times, did not cause any obvious adverse effects on the dogs’ normal physiological functions or result in significant damage to the intra-abdominal organ tissues. However, intraperitoneal hyperthermic perfusion with 43°C saline plus cisplatin for 1 hour, administered three times, exerted varying degrees of adverse effects on the dogs’ vital signs and hepatic and renal function, with varying degrees of injury observed in the liver, kidneys, spleen, and intestinal tissues. Conclusion: The experiments confirmed that 42°C to 42.5°C is the safe temperature range for HIPEC treatment, and an intraperitoneal temperature of 42.5°C is the most effective temperature for HIPEC.

Animal Study Comparing Flow Rates and Temperatures in Intraperitoneal Hyperthermic Perfusion Chemotherapy Using Three Different Catheterization Techniques

Figure: Animal experiments with different catheterization methods

Objective: To compare, via animal experiments, the differences in perfusion flow rate and intracavitary temperature between surgical catheter placement and percutaneous intra-abdominal puncture catheterization during hyperthermic intraperitoneal chemotherapy (HIPEC).

Conclusion: Although the catheter diameters used in percutaneous, intraperitoneal HIPEC performed under local anesthesia are smaller than those used in surgical HIPEC, both the two-point and four-point percutaneous approaches can achieve flow rates and intracavitary temperatures comparable to those of surgical HIPEC. Moreover, percutaneous HIPEC is less invasive and more reproducible than surgical HIPEC, making it worthy of wider clinical adoption.

“In Vivo Experimental Study on Microcirculation in Mice via Hot Perfusion”

Figure: Thermal Perfusion Microcirculation Animal Experiment

Experiments have confirmed that Good Doctor has adopted the original microcirculation thermal perfusion (circulation with a cavity volume ≤100 ml) technology, precisely constructed a microthermal perfusion circulation system using the mouse peritoneal cavity as a model, and successfully carried out microcirculation thermal perfusion therapy.

Clinical Hospital + Clinical Treatment

Figure: Eight Major Clinical Bases for Hot Perfusion by Good Doctor

Drawing on clinical practice, Good Doctor’s research team pioneered “intracavitary temperature monitoring,” abandoning the traditional method of relying solely on temperature measurements at the body’s inlet and outlet to determine the abdominal cavity treatment temperature. Instead, they directly monitor the actual temperature in the treatment area, thereby fundamentally addressing the issue of “precise external control but uncontrolled and drifting internal conditions.” This ensures an effective treatment temperature and maximizes the heat-sensitizing effect of drugs at that temperature.

Truly bring “effective therapeutic temperature” into clinical practice.

Figure: Display of intracavitary temperature monitoring on the GDHIPEC screen

Engage in global cooperation

Good Doctor machines have successfully collaborated with foreign medical institutions.

Photo: Austrian thermotherapy expert Dr. Kleef Photo: Malaysian Dr. Radzi

Achieved comprehensive nationwide coverage, with a cumulative total of over 10,000 clinical treatment cases in both internal and surgical specialties.

Patented technology

The product boasts more than 20 proprietary intellectual property rights, including five invention patents; additionally, patent applications have been filed and granted in Australia, Germany, Russia, the United States, the European Union, South Korea, Canada, and various African countries.

Product Iteration

Based on precise data from clinical practice feedback, Xi’an Good Doctor Medical has continuously invested in R&D and innovation, constantly upgrading its intracavitary hyperthermic perfusion machine to better meet the needs of clinical diagnosis and treatment.

One of the technical advantages is the effective treatment temperature.

The differential thermotolerance between tumors and normal tissues underpins the theoretical rationale for hyperthermic intraperitoneal chemotherapy: it enables precise ablation of cancer cells while sparing normal tissues. Normal tissues exhibit markedly varying thresholds for thermal injury, whereas 42–43°C is universally recognized as the optimal temperature range for tumor hyperthermia; even a deviation of just 0.5°C can compromise therapeutic efficacy or lead to tissue damage.

Figure: Thresholds for Chronic Injury in Various Normal Tissues

Therefore, maintaining the treatment temperature within the effective range is the key to safe and efficient hyperthermic perfusion therapy. Through a series of core technological innovations, Good Doctor has addressed the pain points of temperature fluctuation and uneven distribution in traditional hyperthermic perfusion therapy, achieving precise setting and consistent maintenance of the effective treatment temperature throughout the procedure.

Precise temperature control, tailored to diverse clinical scenarios: the temperature-control range covers the full spectrum, meeting the temperature requirements of different treatment phases and accommodating a wide array of body-cavity therapeutic applications.

Ultimate precision, far exceeding industry standards: real-time temperature display accuracy of ±0.1°C and temperature control accuracy of ±0.1°C; featuring an invention-patented, non-contact 360° omnidirectional rotating heating system combined with dual-loop temperature-control technology to precisely and stably maintain the perfusate temperature within the body cavity at the target setpoint, effectively eliminating temperature drift.

Multi-dimensional temperature monitoring with real-time data support: A comprehensive, multi-dimensional temperature-monitoring system is established, equipped with high-precision probes and ultra-high-accuracy sensors to continuously capture temperature fluctuations throughout the procedure. This provides real-time data for dynamic temperature control, thereby ensuring the efficacy and safety of thermal perfusion therapy.

AI-Driven Closed-Loop Control with Millisecond Response: Leveraging advanced AI algorithms, the system enables dynamic closed-loop temperature control with millisecond-level automatic adjustments. Combined with high-flow circulation and a robust safety alert mechanism, it comprehensively eliminates the risk of temperature anomalies.

Rapid temperature rise with precisely controlled treatment duration: Utilizing advanced anti-interference constant-temperature control technology, the system remains unaffected by external environmental factors, achieving rapid heating to the effective therapeutic temperature of 42–43°C within 3–5 minutes. This ensures stable and controllable maintenance of the 60-minute effective hyperthermia treatment duration, providing a safe, efficient, and reproducible thermal perfusion therapy for clinical use.

Figure: Clinical application scenarios of Good Doctor’s GDHIPEC hyperthermic intraperitoneal chemotherapy

A millennium of thermal therapy research traces its origins, underpinned by a century of technological evolution. From initial theoretical conjectures to rigorous scientific validation and ultimately to clinical application that benefits patients, intracavitary hyperthermic perfusion therapy has traversed a long and groundbreaking journey in humanity’s fight against cancer—a journey that embodies the unwavering dedication of medical professionals and the hopeful expectations of countless patients.

As a cutting-edge clinical device, the Xi’an Good Doctor Intraperitoneal Hyperthermic Perfusion System (GDHIPEC) boasts particularly significant advantages—not only has it achieved a key breakthrough in the core technology of “effective treatment temperature,” but it is also compatible with various clinical scenarios, including aqueous and anhydrous treatments, as well as surgical and interventional puncture catheterization, thereby meeting the treatment needs of different cancer patients. It truly realizes the core diagnostic and therapeutic goals of “multi-cavity, minimal trauma, metastasis control, and pleural effusion management,” providing a more efficient and safer new approach for clinical oncology treatment.

In the future, Good Doctor Thermal Perfusion will continue to stay true to its original aspiration and responsibility in national healthcare, delve into the innovative upgrading and clinical popularization of body cavity thermal perfusion technology, rely on medical experts and academic societies to continuously develop more standardized treatment plans and provide more attentive medical services, empower medical institutions at all levels in all aspects, leverage technological innovation to boost China’s self-reliance and strength in medical science and technology, and write a new chapter in safeguarding human health.
(Some images are sourced from the internet; copyright belongs to the original authors. Please contact us for removal if there is any infringement.)